ArticleJournal of clinical medicine2023
Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Serum adropin and miR-21 expression as predictors of endothelial dysfunction in type 2 diabetes mellitus and vascular complications.Scientific reports · 2025Article
- Adropin as a Marker in Type 2 Diabetes: Insights Into Diabetic Kidney Disease and Chronic Heart Failure.Cureus · 2025Article
- The Association of Adropin with Asymptomatic Coronary Calcification in Patients in Early Stages of Chronic Kidney Disease.International journal of molecular sciences · 2025Article
- Low levels of adropin are associated with acute kidney injury after decongestion in patients with acutely decompensated heart failure.Journal of molecular and cellular cardiology plus · 2025Article
- Measurement of serum adropin levels in chronic renal failure patients receiving routine hemodialysis treatment.Medicine · 2025Observational
- Chronic Kidney Disease and Osteoarthritis: Current Understanding and Future Research Directions.International journal of molecular sciences · 2025Review
- Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression.Frontiers in endocrinology · 2025Article
- Role of the Unique Secreted Peptide Adropin in Various Physiological and Disease States.Biomolecules · 2024Review
- The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme Inhibitors.Iranian journal of medical sciences · 2024Article
- Unveiling the multifaceted role of adropin in various diseases (Review).International journal of molecular medicine · 2024Review
- Adropin: A crucial regulator of cardiovascular health and metabolic balance.Metabolism open · 2024Review
- Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides.Diagnostics (Basel, Switzerland) · 2024Article
- Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases.The Journal of international medical research · 2024Review
- Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure.Advances in therapy · 2024Article
- Clinical Significance of Adropin and Afamin in Evaluating Renal Function and Cardiovascular Health in the Presence of CKD-MBD Biomarkers in Chronic Kidney Disease.Diagnostics (Basel, Switzerland) · 2023Article
- Serum Adropin Levels and Body Mass Composition in Kidney Transplant Recipients-Are There Sex Differences?Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adropin is a multifunctional secreted protein, which is involved in the metabolic modulation of the heart-brain-kidney axis in heart failure (HF). The aim of the study was to detect the plausible predictive value of serum levels of adropin for chronic kidney disease (CKD) grades 1-3 in type 2 diabetes mellitus (T2DM) patients with chronic HF. We enrolled 417 T2DM individuals with chronic HF and subdivided them into two groups depending on the presence of CKD. The control group was composed of 25 healthy individuals and 30 T2DM patients without HF and CKD. All eligible patients underwent an ultrasound examination. Adropin was detected by ELISA in blood samples at the study baseline. We found that adropin levels in T2DM patients without HF and CKD were significantly lower than in healthy volunteers, but they were higher than in T2DM patients with known HF. The optimal cut-off point for adropin levels was 2.3 ng/mL (area under the curve [AUC] = 0.86; 95% CI = 0.78-0.95; sensitivity = 81.3%, specificity = 77.4%). The multivariate logistic regression adjusted for albuminuria/proteinuria showed that serum levels of adropin <2.30 ng/mL (OR = 1.55;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.